Rwanda, Merck & Co., Inc. (MRK) and QIAGEN Inc. (QGEN) Launch Africa‚Äôs First Comprehensive Cervical Cancer Prevention Program Incorporating Both HPV Vaccination and HPV Testing  
4/25/2011 8:37:47 AM

WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--The Government of Rwanda, together with QIAGEN N.V. (NASDAQ: QGEN, F:QIA) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the launch, in Kigali, Rwanda, of a comprehensive national cervical cancer prevention program that includes vaccination with GARDASIL [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] for appropriate girls 12 to 15 years of age and modern molecular diagnostic screening for women between the ages of 35 and 45.